• Please log in or register to access this feature.
You have free access to this content

Risperidone in the treatment of mixed state bipolar patients: Results from a 24-week, multicenter, open-label study in Korea

  1. Young Sup Woo md 1,
  2. Won-Myong Bahk md 1,*,
  3. Duk-In Jon md 5,
  4. Sang-Keun Chung md 6,
  5. Sang-Yeol Lee md 7,
  6. Yong Min Ahn md 2,
  7. Chi-Un Pae md 1,
  8. Hyun-Sang Cho md 3,
  9. Jeong-Gee Kim md 8,
  10. Tae-Yeon Hwang md 9,
  11. Hong-Seok Lee md 5,
  12. Kyung Joon Min md 4,
  13. Kyung-Uk Lee md 1,
  14. Bo-Hyun Yoon md 10

Article first published online: 4 NOV 2009

DOI: 10.1111/j.1440-1819.2009.02026.x

Issue

Psychiatry and Clinical Neurosciences

Psychiatry and Clinical Neurosciences

Volume 64, Issue 1, pages 28–37, February 2010

Additional Information

How to Cite

Woo, Y. S., Bahk, W.-M., Jon, D.-I., Chung, S.-K., Lee, S.-Y., Ahn, Y. M., Pae, C.-U., Cho, H.-S., Kim, J.-G., Hwang, T.-Y., Lee, H.-S., Min, K. J., Lee, K.-U. and Yoon, B.-H. (2010), Risperidone in the treatment of mixed state bipolar patients: Results from a 24-week, multicenter, open-label study in Korea. Psychiatry and Clinical Neurosciences, 64: 28–37. doi: 10.1111/j.1440-1819.2009.02026.x

Author Information

  1. 1

    Department of Psychiatry, College of Medicine, Catholic University of Korea,

  2. 2

    Department of Psychiatry, Seoul National University Hospital,

  3. 3

    Department of Psychiatry, Yonsei University, College of Medicine,

  4. 4

    Department of Neuropsychiatry, College of Medicine, Chung-Ang University, Seoul,

  5. 5

    Department of Psychiatry, College of Medicine, Hallym University, Anyang,

  6. 6

    Department of Psychiatry, Chonbuk National University Medical School, Jeonju,

  7. 7

    Department of Neuropsychiatry, College of Medicine, WonKwang University, Iksan,

  8. 8

    Department of Psychiatry, Maryknoll Hospital, Busan,

  9. 9

    Yong-In Mental Hospital, Yongin and

  10. 10

    Naju National Hospital, Naju, Korea

* *Won-Myong Bahk, MD, Department of Psychiatry, College of Medicine, Catholic University of Korea, 62 Yoido-Dong, Youngdeungpo-Gu, Seoul 150-713, Korea. Email: wmbahk@catholic.ac.kr

Publication History

  1. Issue published online: 20 JAN 2010
  2. Article first published online: 4 NOV 2009
  3. Received 13 May 2009; revised 13 August 2009; accepted 19 August 2009.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (119K)

Keywords:

  • bipolar disorder;
  • mixed state;
  • mood stabilizer;
  • risperidone

Aims:  The goal of the present study was to evaluate the efficacy of risperidone combined with mood stabilizers for treating bipolar mixed state.

Methods:  The present study was a 24-week, open-label, combination, prospective investigation of the efficacy of risperidone in combination with mood stabilizers. Risperidone (1–6 mg/day) was given in combination with mood stabilizers in flexible doses according to clinical response and tolerability for 114 patients in mixed or manic episode.

Results:  Forty-four patients met our criteria for mixed state bipolar disorder and 70 met the criteria for pure mania. Mean age for the subjects was 39.0 ± 11.0 years and 55.3% were female. The combination of risperidone with mood stabilizers significantly improved the scores on the Young Mania Rating Scale (YMRS), 17-item Hamilton Rating Scale for Depression (HAMD), 18-item Brief Psychiatric Rating Scale (BPRS), Global Assessment Scale (GAS), and Clinical Global Impression Scale for use in bipolar illness Severity (CGI-BP) at 24 weeks (P < 0.0001). Analysis of the YMRS, BPRS, GAS, and CGI-BP scores showed significant improvement in both the manic and mixed groups. The rate of response in YMRS scores was 84.2% (n = 96) and the rate of YMRS remission was 77.2% (n = 88) at week 24 in the total population. Seventy-four patients met both YMRS ≤ 12 and HAMD ≤ 7 at week 24 (64.9%). Risperidone was well tolerated, and adverse events were mostly mild.

Conclusion:  The combination of risperidone with mood stabilizers was an effective and safe treatment for manic symptoms and coexisting depressive symptoms of bipolar disorder.

View Full Article (HTML) Get PDF (119K)